Additionally, TXNIP inhibition, especially in the context of CREB1 overexpression, emerges as an alternative strategy, disrupting redox homeostasis and further sensitizing MM cells to targeted therapies. The gene discussed is TXNIP; the disease is Miyoshi myopathy.